Your AI-Trained Oncology Knowledge Connection!

Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center : Episode 18

BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

March 1, 2024

By Carey K. Anders, MD

Opinion

Video

An overview of the design and rationale for the phase 2 BRIDGET study looking at the addition of tucatinib to HER2-directed antibody therapy in breast cancer.

EP: 1.Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

EP: 2.Approaches for 1L Therapy and Restaging in Triple-Positive mBC

EP: 3.The Role of Radiotherapy in HER2+ mBC

EP: 4.Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond

EP: 5.Treatment Considerations and AE Management Strategies with HER2-Directed Therapies

EP: 6.Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases

EP: 7.HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

EP: 8.BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

EP: 9.Strategies for AE Management with Tucatinib in Breast Cancer

EP: 10.D-TORCH: Topical Diclofenac for Reducing Hand Foot Syndrome with Capecitabine

EP: 11.Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases

EP: 12.Advancements in Treating Brain Metastases in HER2+ Breast Cancer

EP: 13.Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

EP: 14.Strategies for AE Management with T-DXd in Breast Cancer

EP: 15.Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast Cancer

EP: 16.Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer

EP: 17.Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer

Now Viewing

EP: 18.BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

EP: 19.Future Perspectives on HER2+ Breast Cancer Treatment

EP: 20.Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!